Faster, more accurate tuberculosis test developedOctober 12, 2006Test takes an average of seven days to complete Researchers from the Johns Hopkins Bloomberg School of Public Health, the Imperial College London, Universidad Peruana Cayetano Heredia, in Lima, Peru, and other institutions have developed a simple and rapid new tuberculosis (TB) test. The test, called microscopic-observation drug-susceptibility or MODS, is more sensitive, faster and cheaper to perform than current culture-based tests. The study is published in the October 12, 2006, issue of the New England Journal of Medicine. "In the fight to stop the spread of TB, new diagnostic tools are urgently needed to detect TB and multidrug-resistant TB. MODS is just such a tool. It will change the practice of TB testing in developing countries," said Robert H. Gilman, MD, senior author of the study and a professor in the Bloomberg School of Public Health's Department of International Health.
From April 2003 to July 2004, the study authors collected 3,760 sputum-saliva mixed with respiratory discharge-in order to complete sensitivity and susceptibility studies of the MODS test. All samples were decontaminated and then used for parallel MODS testing, as well as for two current gold standard TB tests- the Lowenstein-Jensen culture and automated mycobacterial culture (using the MBBacT system). In order to test the samples using MODS, the researchers observed the cultures under an inverted light microscope for 40 days. The sensitivity of detecting TB was 97.8 percent for MODS culture, 89 percent for automated mycobacterial culture and 84 percent for Lowenstein-Jensen culture, when compared to each other. The median time for detection of TB was 7 days for MODS culture, 13 days for automated mycobacterial culture and 26 days for Lowenstein-Jensen culture. The researchers also introduced isoniazid, rifampin, ethambutol and streptomycin-TB antibiotics-to the cultures in order to detect drug-resistant TB. Compared to standard culture reference methods, drug-resistant susceptibility agreement for MODS was 100 percent for rifampin, 97 percent for isoniazid, 99 percent for rifampin and isoniazid (combined for multi-drug resistance), 95 percent for ethambutol and 92 percent for streptomycin. MODS results were available, on average, in seven days, making them clinically relevant. Standard antimicrobial tests can take up to several months. The MODS test relies on three principles: (1) Mycobacterium tuberculosis grows faster in liquid medium than in solid medium; (2) TB grows in characteristic tangles or coils and these characteristic cord formations can be seen microscopically in liquid medium; and (3) the ability to incorporate drugs permits rapid and direct drug-susceptibility testing at the same time as the detection of bacterial growth. Over 5,000 people die of TB every day worldwide and the poor are disproportionately affected, explained David A.J. Moore, MD, lead author of the study and senior lecturer in infectious diseases and tropical medicine at Imperial College London. \\\ Johns Hopkins University Bloomberg School of Public Health Science News and Science Current Events Tag Cloud This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size. | |||||||||||||||||||||
|
Related Tuberculosis Current Events and Tuberculosis News Articles Harvard scientists solve mystery about why HIV patients are more susceptible to TB infection A team of Harvard scientists has taken an important first step toward the development of new treatments to help people with HIV battle Mycobacterium tuberculosis (TB) infection. Measurements fail to identify TB patients who could benefit from shorter treatment course Tuberculosis (TB) is a difficult infection to treat and requires six months of multiple antibiotics to cure it. To combat the TB pandemic, a shorter and simpler drug treatment would be a huge advance since most TB occurs in resource-limited settings with poor public health infrastructures. Carb synthesis sheds light on promising tuberculosis drug target A fundamental question about how sugar units are strung together into long carbohydrate chains has also pinpointed a promising way to target new medicines against tuberculosis. Global health funding soars, boosted by unprecedented private giving Well-heeled donors, private corporations and average citizens sending money to their favorite charities are changing the landscape of global health funding. 3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis Three new studies have individually shown the anti-TNF (tumour necrosis factor) therapy etanercept to be effective, with a good safety profile, in children under four years of age with juvenile idiopathic arthritis (JIA). Unexpected discovery can open a new chapter in the fight against tuberculosis A close relative of the microorganism that causes tuberculosis in humans has been found to form spores. TB -- hiding in plain sight Current research suggests that Mycobacterium tuberculosis can evade the immune response. Study suggests TB screening needs to be targeted for maximum public health benefit New estimates of the likelihood that a latent case of tuberculosis (TB) will become active have resulted in a roughly 50 percent increase over previous estimates of the number of people needed to be screened (NNS) to prevent an active infection, limiting the cost effectiveness of screening in many Center for Disease Control and Prevention (CDC)-defined risk groups. TB vaccine gets its groove back A team of Vanderbilt University Medical Center investigators has cracked one of clinical medicine's enduring mysteries - what happened to the tuberculosis vaccine. Filling the gap: The importance of Medicaid continuity for former inmates It is time for states to suspend, rather than terminate, the Medicaid benefits of inmates while they are incarcerated, say correctional health care experts from The Miriam Hospital in a commentary published online by the Journal of General Internal Medicine. More Tuberculosis Current Events and Tuberculosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||